SummaryRMgm-5186
|
||||||||||
*RMgm-5186| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging, Introduction of a transgene |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 35162991 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | RMgm-1026 |
| Other information parent line | A drug-selectable marker free reporter line expressing GFP under the constitutive hsp70 promoter |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Witte de C, Khalife J |
| Name Group/Department | Center for Infection and Immunity of Lille |
| Name Institute | Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille |
| City | Lille |
| Country | France |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5186 |
| Principal name | PbI2-mCherry |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Genotyping analysis showed the correct integration of the tagged PbI2 and the expression of mCherry–PbI2 was checked by immunoblot using anti-RFP antibody. |
| Gametocyte/Gamete | Genotyping analysis showed the correct integration of the tagged PbI2 and the expression of mCherry–PbI2 was checked by immunoblot using anti-RFP antibody. |
| Fertilization and ookinete | Not tested |
| Oocyst | Not tested |
| Sporozoite | Not tested |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Phenotype
Genotyping analysis showed the correct integration of the tagged PbI2 and the expression of mCherry–PbI2 was checked by immunoblot using anti-RFP antibody.
Additional information Other mutants |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1218500 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0320000 | ||||||||||||||||||||||||||
| Gene product | protein phosphatase inhibitor 2 | ||||||||||||||||||||||||||
| Gene product: Alternative name | PbI2, I2 | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | mCherry | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | The Plasmodium berghei strain used in this study was a PbGFP ANKA line kindly provided by O. Silvie (Université Pierre et Marie Curie, Paris, France). Plasmid pL1886 was given by B. Franke-Fayard (Leiden University Medical Center, Leiden, The Netherlands. The generation of a P. berghei line expressing mCherry-tagged PP1c has previously been reported. As for PbI2, a parasite line expressing mCherry-tagged I2 from its endogenous locus was generated in the same strain used for PbPP1c. A C-terminal mCherry-tagged PbI2 was generated by single homologous recombination of a 1436 pb region of PbI2 without the stop codon (Pr3–Pr2) inserted into the pL1886 vector and NdeI-linearized before transfection into the PbGFP ANKA strain | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
Transgene: Mutant parasite expressing a transgene| top of page | |||||||||||||||||||
| Type and details of transgene | |||||||||||||||||||
| Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
| Transgene name | GFP | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||
| Selectable marker used to select the mutant parasite | No selectable marker | ||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
| Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
| Additional remarks genetic modification | The parasites are selected by a combination of positive selection (pyrimethamine), negative selection (5-FC) and FACS sorting. 1) Transfected parasites are first selected in a mouse by pyrimethamine treatment 2) GFP+mCherry+ parasites are selected by FACS sorting and used to infect a mice 3) This mouse is treated with 5-FC to select for parasites that have the selectable marker removed 4) GFP+mCherry- and marker free parasites are selected by FAC sorting and used to infect a mouse | ||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Other details transgene | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Promoter | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_0711900 | ||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0818900 | ||||||||||||||||||
| Gene product | heat shock protein 70 | ||||||||||||||||||
| Gene product: Alternative name | HSP70 | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
| 3'-UTR | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
| Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
| Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
| Insertion/Replacement locus | |||||||||||||||||||
| Replacement / Insertion | Replacement locus | ||||||||||||||||||
| Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
| Gene product | 6-cysteine protein | ||||||||||||||||||
| Gene product: Alternative name | P230p | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||